Press release
Fabry Disease Market Forecast 2032: FDA Approvals, Clinical Trials, Pipeline, Epidemiology and Companies by DelveInsight | PRX-102 (Pegunigalsidase Alfa), Venglustat, ST-920, FLT190, 4D-310, more
Fabry Disease Market
(Albany, USA) DelveInsight's "Fabry Disease Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of Fabry Disease, historical and forecasted epidemiology as well as the Fabry Disease market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.
The Fabry Disease market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Fabry Disease market size from 2019 to 2032, segmented by seven major markets. The Report also covers current Fabry Disease treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Fabry Disease market.
Request for a Free Sample Report @ [https://www.delveinsight.com/report-store/neuropathic-pain-market?utm_source=benzinga&utm_medium=pressrelease&utm_campaign=apr]
Some facts of the Fabry Disease Market Report are:
* According to DelveInsight, Fabry Disease market size is expected to grow at a decent CAGR by 2032.
* As per DelveInsight analysis, the Fabry disease market size in the 7MM was approximately USD ~1.3 billion in 2022.
* As per the analysis conducted by DelveInsight, in 2022 the total diagnosed prevalent cases of Fabry disease was 15,290 in the 7MM and these cases are further projected to increase during the study period (2019-2032).
* Leading Fabry Disease companies working in the market are Protalix Biotherapeutics, Sanofi Genzyme, Sangamo Therapeutics, Freeline Therapeutics, 4D Molecular Therapeutics, Idorsia Pharmaceuticals, GREENOVATION BIOTECH GMBH, Shire, Takeda, Amicus Therapeutics, Protalix, uniQure, Codexis, MP6 Therapeutics, CellGenTech, and others.
* Key Fabry Disease Therapies expected to launch in the market are PRX-102 (Pegunigalsidase Alfa), Venglustat, ST-920, FLT190, 4D-310, Lucerastat, Moss-aGal, and others.
* On March 2024, Sanofi announced results of a Phase 4 study which evaluates the safety and tolerability of Fabrazyme at current approved dose with increases in the infusion rate and reduced infusion volume. This study aims to generate data to provide the guidance on how infusion rate can be safely increased and minimize the burden of the life-long treatment with Fabrazyme.
* On April 2024, 4D Molecular Therapeutics announced results of an Open-Label, Phase 1/2a Trial of Gene Therapy 4D-310 in Adults With Fabry Disease and Cardiac Involvement
Fabry Disease Overview
Fabry disease is an inherited lysosomal storage disorder caused by a nonfunctional or partially functional enzyme called alpha-galactosidase A (-Gal A). Reduced -Gal A activity in lysosomes leads to the accumulation of enzyme substrates (Gb3 and lyso-Gb3), which causes cellular damage in tissues throughout the body.
Despite being X-linked, heterozygous women may experience all of the signs and symptoms seen in men; however, when compared to hemizygous males, the signs and symptoms of Fabry disease in women typically appear later and with less severity.
Fabry disease symptoms include pain that spreads throughout the body (called a Fabry crisis), gastrointestinal complications, headaches, impaired sweating, vertigo, and hearing loss. Several tests, such as enzyme assay and newborn screening, are used for Fabry disease diagnosis.
Learn more about Fabry Disease treatment algorithms in different geographies, and patient journeys. Contact to receive a sample @ [https://www.delveinsight.com/sample-request/fabry-disease-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]
Fabry Disease Market
The Fabry Disease market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted Fabry Disease market trends by analyzing the impact of current Fabry Disease therapies on the market and unmet needs, and drivers, barriers, and demand for better technology.
This segment gives a thorough detail of the Fabry Disease market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Fabry Disease market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, the Fabry Disease market in 7MM is expected to witness a major change in the study period 2019-2032.
Fabry Disease Epidemiology
The Fabry Disease epidemiology section provides insights into the historical and current Fabry Disease patient pool and forecasted trends for seven individual major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Fabry Disease market report also provides the diagnosed patient pool, trends, and assumptions.
Explore more about Fabry Disease Epidemiology @ [https://www.delveinsight.com/report-store/fabry-disease-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]
As per DelveInsight's assessments, in the 7MM Fabry Disease is more prevalent in males than in females but there are some differences at the regional level
Fabry Disease Drugs Uptake
This section focuses on the uptake rate of the potential Fabry Disease drugs recently launched in the Fabry Disease market or expected to be launched in 2019-2032. The analysis covers the Fabry Disease market uptake by drugs, patient uptake by therapies, and sales of each drug.
Fabry Disease Drugs Uptake helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs and allows the comparison of the drugs based on Fabry Disease market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Fabry Disease Pipeline Development Activities
The Fabry Disease report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses Fabry Disease key players involved in developing targeted therapeutics.
Request for a sample report to understand more about the Fabry Disease pipeline development activities @ [https://www.delveinsight.com/sample-request/fabry-disease-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]
Fabry Disease Pipeline Therapies and Key Companies
* PRX-102 (Pegunigalsidase Alfa): Protalix Biotherapeutics
* Venglustat: Sanofi Genzyme
* ST-920: Sangamo Therapeutics
* FLT190: Freeline Therapeutics
* 4D-310: 4D Molecular Therapeutics
* Lucerastat: Idorsia Pharmaceuticals
* Moss-aGal: GREENOVATION BIOTECH GMBH
Fabry Disease Therapeutics Assessment
Major key companies are working proactively in the Fabry Disease Therapeutics market to develop novel therapies which will drive the Fabry Disease treatment markets in the upcoming years are
Learn more about the emerging Fabry Disease therapies & key companies @ [https://www.delveinsight.com/sample-request/fabry-disease-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]
Fabry Disease Report Key Insights
1. Fabry Disease Patient Population
2. Fabry Disease Market Size and Trends
3. Key Cross Competition in the Fabry Disease Market
4. Fabry Disease Market Dynamics (Key Drivers and Barriers)
5. Fabry Disease Market Opportunities
6. Fabry Disease Therapeutic Approaches
7. Fabry Disease Pipeline Analysis
8. Fabry Disease Current Treatment Practices/Algorithm
9. Impact of Emerging Therapies on the Fabry Disease Market
Table of Contents
1. Key Insights
2. Executive Summary
3. Fabry Disease Competitive Intelligence Analysis
4. Fabry Disease Market Overview at a Glance
5. Fabry Disease Disease Background and Overview
6. Fabry Disease Patient Journey
7. Fabry Disease Epidemiology and Patient Population
8. Fabry Disease Treatment Algorithm, Current Treatment, and Medical Practices
9. Fabry Disease Unmet Needs
10. Key Endpoints of Fabry Disease Treatment
11. Fabry Disease Marketed Products
12. Fabry Disease Emerging Therapies
13. Fabry Disease Seven Major Market Analysis
14. Attribute Analysis
15. Fabry Disease Market Outlook (7 major markets)
16. Fabry Disease Access and Reimbursement Overview
17. KOL Views on the Fabry Disease Market
18. Fabry Disease Market Drivers
19. Fabry Disease Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=fabry-disease-market-forecast-2032-fda-approvals-clinical-trials-pipeline-epidemiology-and-companies-by-delveinsight-prx102-pegunigalsidase-alfa-venglustat-st920-flt190-4d310-more]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/conference-coverage-services
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Fabry Disease Market Forecast 2032: FDA Approvals, Clinical Trials, Pipeline, Epidemiology and Companies by DelveInsight | PRX-102 (Pegunigalsidase Alfa), Venglustat, ST-920, FLT190, 4D-310, more here
News-ID: 3515657 • Views: …
More Releases from ABNewswire
Author's Tranquility Press Unveils "The Death of the Terror Bird" at the 2025 Ma …
A Sci-Fi Survival Thriller Where Prehistoric Beasts, Alien Civilizations, and the Human Spirit Collide - Now Available on Amazon and Featured at Asia's Largest Book Festival
Author's Tranquility Press proudly announces the international release of The Death of the Terror Bird [https://www.amazon.com/Death-Terror-Bird-Mark-Buhler/dp/1967776350/ref=sr_1_1?crid=23JWHZBBA3WBC&dib=eyJ2IjoiMSJ9.JqEy4B3zuMSVdijZjmDXtA.pPJxKRMw9I4dvd-0Btpkq5R_nwx2CVowSFbXJy_S-_E&dib_tag=se&keywords=death+of+the+terror+bird+mark&qid=1755715471&s=books&sprefix=death+of+the+terror+bird+mark%2Cstripbooks%2C531&sr=1-1] by Mark De Klerk Buhler, a genre-defying novel that fuses science fiction, historical suspense, and human drama into a white-knuckle reading experience. Readers in the Philippines and across Asia…
Libas Collective Exploring the Growth of the Second-Hand Luxury Market
The luxury fashion market has long defined exclusivity, classic workmanship, and social standing. However, it is only recently that a new wave of consumer behavior has altered the relationship between individuals and luxury goods. What used to be seen as somewhat peripheral for enthusiasts has now turned into a global movement: the second-hand luxury market [https://www.libascollective.com/]. More than just buying, today it speaks of cultural identity, sustainability, and a redefined…
Inlex Partners: Key Benefits of Setting Up a Business in Dubai and the UAE for I …
The United Arab Emirates (UAE), and Dubai in particular, has rapidly become one of the most attractive destinations for entrepreneurs, startups, and international corporations. With expert support from Inlex Partners - business setup services in Dubai [https://inlex-partners.com/], international investors can navigate company formation, banking, and licensing with confidence. Positioned at the crossroads of Europe, Asia, and Africa, the UAE serves as a natural hub for global trade and investment.
Known for…
Funk Fest Returns to New Orleans This October with Three Days of Funk, Food, and …
Funk Fest returns to New Orleans October 17-19, 2025, with three days of nonstop groove at Spanish Plaza. Featuring three stages of authentic NOLA funk including Galactic, Dumpstaphunk, Master P with the Soul Rebels, George Porter Jr., and Big Chief Juan Pardo's Tribal Gold the festival blends legendary music with the city's cultural heartbeat. From Black Masking Indians to immaculate vibes and tasty food, Funk Fest is New Orleans at…
More Releases for Fabry
U.S. Fabry Disease Market Size Report 2034
On April 28, 2025, Exactitude Consultancy., Ltd. released a research report titled "U.S. Fabry Disease Market". This report covers the global U.S. Fabry Disease market sales, sales volume, price, market share, ranking of major companies, etc., and provides a detailed analysis by region, country, product type, and application. It also forecasts the market size of automotive kick sensors based on market patterns from 2020 to 2034 and future market trends.…
Top Factor Driving Fabry Disease Treatment Market Growth in 2025: Impact of Incr …
How Are the key drivers contributing to the expansion of the fabry disease treatment market?
The rising prevalence of renal diseases is expected to drive the growth of the Fabry disease treatment market. Renal diseases are becoming more prevalent due to genetic factors, lifestyle choices, and environmental influences. Fabry disease, which causes kidney dysfunction, is increasing and requires timely intervention. According to the Australian Bureau of Statistics, kidney disease affected 246,200…
Fabry Disease Market Trends Analysis 2030
Fabry disease is a rare X-linked lysosomal storage disorder. This patient has a deficiency in the enzyme alpha galactosidase, which progresses to organ failure. The development of fabry illnesses is mostly caused by abnormal accumulation of a certain fatty substance known as globotriaosylceramide. This aberrant buildup can be detected in the skin, eyes, heart, kidney, brain, gastrointestinal system, and central nervous system, among other body parts.
Galactosidase Alpha (GLA) is a…
Fabry Disease Market Pipeline 2019 Analysis and Developmental Stages
"Fabry Disease - Pipeline Insight, 2019” report offers comprehensive Insight of the pipeline (under development) therapeutics scenario and growth prospects across Fabry Disease development. The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.
Pipeline Products covered across the following Developmental Stages:
- Clinical
- Non-clinical
- Inactive: Discontinued…
Fabry Disease - Pipeline Review, H1 2017
ReportsWorldwide has announced the addition of a new report title Fabry Disease - Pipeline Review, H1 2017 to its growing collection of premium market research reports.
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Fabry Disease - Pipeline Review, H1 2017, provides an overview of the Fabry Disease (Genetic Disorders) pipeline landscape.
Fabry disease is an inherited disorder. Fabry disease results from abnormal deposits of a particular fatty substance (called…
Fabry Disease Market Intelligence Report Offers Growth Prospects
Fabry diseaseis also known as Anderson-Fabry disease and alpha-galactosidase A deficiency. It is a rare genetic disorder of lipid metabolism resulting from the deficient activity of the alpha-galactosidase A (a-Gal A) enzyme. The deficiency of the enzyme is caused by the alterations in the genes that instructs the cells to make alpha-galactosidase A (a-Gal A) enzyme. Fabry disease is known to cause variety of systemic symptoms and complications, one of…
